Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
3.570
-0.090 (-2.46%)
At close: Feb 19, 2026, 4:00 PM EST
3.710
+0.140 (3.92%)
Pre-market: Feb 20, 2026, 8:53 AM EST
Company Description
Exicure, Inc. does not have significant operations.
Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Exicure, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Andy Yoo |
Contact Details
Address: 400 Seaport Court, Suite 102 Redwood City, California 94063 United States | |
| Phone | 847 673 1700 |
| Website | exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M3097 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Josephine Cardarelli Ph.D. | President and Chief Scientific Officer |
| Joshua Miller | Chief Accounting Officer |
| Dr. Devki Sukhtankar Ph.D. | Head of Preclinical Research and Translational Medicine |
| Dr. Niña Caculitan Ph.D. | Head of Clinical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | 8-K | Current Report |
| Feb 10, 2026 | 8-K | Current Report |
| Jan 22, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13D/A | Filing |
| Jan 20, 2026 | SCHEDULE 13D/A | Filing |
| Jan 9, 2026 | SCHEDULE 13D/A | Filing |
| Dec 10, 2025 | SCHEDULE 13G/A | Filing |
| Nov 17, 2025 | 8-K | Current Report |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 7, 2025 | 10-Q | Quarterly Report |